Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 3, 2008, Pages 143-147

  Erdogan M ^b   Karadeniz, M ^a,b   Alper, G E ^b   Tamsel, S ^b   Uluer, H ^b   Caglayan O ^c   Saygili, F ^b   Yilmaz, C ^b  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Cardiovascular risk factors; Polycystic ovary syndrome; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN; TESTOSTERONE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ANDROGEN BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CARBOXYPEPTIDASE U; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; PROLACTIN; REFERENCE VALUES; RISK FACTORS; TESTOSTERONE; TUNICA INTIMA; TUNICA MEDIA;

EID: 42049095880     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992118     Document Type: Article

References (55)

1. Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004; 191 (3): 713-717
2. Legro R. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312
3. Holte J, Gennarelli G, Wide L et al. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 1143-1150
4. Talbott E, Clerici A, Berga SL et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998; 51: 415-422
5. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995; 98: 27S-32S
6. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86:10: 4666-4673
7. Kelly CC, Lyall H, Petrie JR et al. Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:6: 2453-2455
8. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombinactivatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484
9. Mosnier LO, Borne PA von dem, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835
10. Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and nonindependent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1: 791-797
11. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-676
12. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181
13. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y et al. Insulin resistance is associated with increased circulating levels of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665
14. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-639
15. Hamsten A, Faire U de, Walldius G, Dahlen G, Szamosi A, Landou C et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 8549: 3-9
16. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230-237
17. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19 (1): 41-47
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
19. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001; 76 (3): 511-516
20. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 13:103 (10): 1410-1415
21. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87 (2): 742-746
22. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86 (6): 2453-2455
23. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002; 53 (3): 157-162
24. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44 (5): 611-616
25. Tarkun I, Canturk Z, Arslan BC, Tureman E, Tarkun H. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocrinol J 2004; 51 (5): 467-472
26. Muneyyirci-Delale O, Nacharaju VL, Dalloul M, Jalou S, Rahman M, Altura BM, Altura BT. Divalent cations in women with PCOS: implications for cardiovascular disease. Gynecol Endocrinol 2001; 15 (3): 198-201
27. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86 (6): 2453-2455
28. Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34 (10): 2387-2391
29. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3 (10): 2211-2218
30. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34 (4): 1038-1040
31. Silveira K, Schatteman F, Goossens E, Moor S, Scharpe M, Stromqvist et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-368
32. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-1025
33. Zorio R, Castello C, Falco F, Espana A, Osa , Almenar L et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122: 958-965
34. Santamaria A, Martinez-Rubio A, Borrell M, Mateo J, Ortin R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 2004; 89: 880-881
35. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-873
36. Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 2005; 27 [Epub ahead of print]
37. Santamaria A, Martinez-Rubio A, Borrell M, Mateo J, Ortin R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 2004; 89 (7): 880-881
38. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-368
39. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA. Women with polycystic ovary syndrome wedge respected in 1956-1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57 (3): 505-513
40. Santamaria A, Borrell M, Oliver A, Ortin R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population. Am J Hematol 2004; 76 (4): 348-352
41. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88 (6): 1020-1025
42. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology (Oxford) 2000; 52: 595-600
43. Dahlgren E, Johansson S, Lindstedt G et al. Women with polycystic ovary syndrome wedge resected in 1956-1965: a long-term follow-up focusing on natural history and circulating hormones. Fertility and Sterility 1992; 57: 505-513
44. Christian RC, Dumesic DA, Behrenbeck T et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2562-2568
45. Talbott E, Zborowski JV, MacHugh-Pemu K et al Metabolic cardiovascular syndromeand its relationship to coronary calcification in women with polycystic ovarian syndrome. Presented at Third International Workshop on Insulin Resistance, New Orleans, LA 2003
46. Talbott EO, Zborowski JV, Rager JR et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5454-5461
47. Talbott EO, Guzick DS, Sutton-Tyrrell K et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middleaged women. Arteriosclerosis Thrombosis and Vascular Biology 2000; 20 (11): 2414-2421
48. Solomon CG, Hu FB, Dunaif A et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87 (5): 2013-2017
49. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87 (2): 660-665
50. Yano Y, Kitagawa N, Gabazza EC, Morioka K, Urakawa H, Tanaka T, Katsuki A, Araki-Sasaki R, Hori Y, Nakatani K, Taguchi O, Sumida Y, Adachi Y. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88 (2): 736-741
51. Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and nonindependent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1 (4): 791-797
52. Alexandraki K, Protogerou AD, Papaioannou TG, Piperi C, Mastorakos G, Lekakis J, Panidis D, Diamanti-Kandarakis E. Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones (Athens) 2006; 5 (2): 126-136
53. Orio F, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 4588-4593
54. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 1 2005; 20 (9): 2409-2413
55. Talbott E, Guzick D, Sutton-Tyrrell K, McHugh-Pemu K, Zborowski J, Remsberg K, Kuller L. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-2421